 Inclusion Criteria: - Pathologically confirmed diagnosis of malignancy solid tumour suitable for treatment with intensified carboplatin and paclitaxel - Previously untreated with chemotherapy or radiotherapy - ECOG performance status 0 to 2 inclusive - Life expectancy greater than or equal to 12 weeks - ANC greater than or equal to 2.0 x 109L, platelets greater than 100 x 109L - Glomerular filtration rate greater than 60 mLmin Exclusion Criteria: - Active infection requiring treatment with systemic IV or oral anti-infectives antibiotic, antifungal, antiviral within 72 hours of randomisation - Known to be HIV positive - Any premalignant myeloid condition or any malignancy with myeloid characteristics e.g., myelodysplastic syndromes, acute or chronic myelogenous leukaemia - Prior malignancy within the last 5 years, with the exception of surgically cured basalsquamous skin cell carcinoma, andor carcinoma of the cervix in-situ - History of impaired cardiac status e.g., severe heart disease NYHA greater than 2, cardiomyopathy, or congestive heart failure - Bone marrow involvement of disease - Major surgery within 2 weeks before randomisation - Known sensitivity to E. coli derived drug products e.g., filgrastim - Previous exposure to pegfilgrastim 